Daclizumab induction in liver transplant recipients.
Heffron
T G
TG
Department of Surgery, Emory University School of Medicine, Atlanta, Georgia, USA.
Smallwood
G A
GA
de Vera
M E
ME
Davis
L
L
Martinez
E
E
Stieber
A C
AC
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000077561:Daclizumab; D004334:Drug Administration Schedule; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage*; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007674:Kidney Diseases / Q000139:chemically induced / Q000517:prevention & control*; D016031:Liver Transplantation / Q000276:immunology*; D008875:Middle Aged; D011183:Postoperative Complications / Q000139:chemically induced / Q000517:prevention & control*; D011446:Prospective Studies; D016559:Tacrolimus / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000077561:Daclizumab; D016559:Tacrolimus